A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus

Advances in Skin and Wound Care

Volumn 27, Issue 12, 2014, Pages 548-559

  Tanus, Tonny ^a,b   Scangarella Oman, Nicole E ^c   Dalessandro, Marybeth ^c   Li, Gang ^c   Breton, John J ^c   Tomayko, John F ^c  

^a Allergy Medical Clinic   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Impetigo; Linezolid; Methicillin resistant Staphylococcus aureus; Retapamulin; Secondarily infected traumatic lesions

Indexed keywords

ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS; LINEZOLID; OINTMENT; RETAPAMULIN;

ADMINISTRATION AND DOSAGE; ADOLESCENT; ADULT; AGED; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; HUMAN; IMPETIGO; INFANT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEWBORN; OINTMENT; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL SKIN INFECTIONS; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; VERY ELDERLY; WOUNDS AND INJURIES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMPETIGO; INFANT; INFANT, NEWBORN; LINEZOLID; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OINTMENTS; STAPHYLOCOCCAL SKIN INFECTIONS; TREATMENT OUTCOME; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84927660489     PISSN: 15277941     EISSN: 15388654     Source Type: Journal    
DOI: 10.1097/01.ASW.0000456631.20389.ae     Document Type: Article

References (34)

1. Silverberg N, Block S. Uncomplicated skin and skin structure infections in children: diagnosis and current treatment options in the United States. Clin Pediatr (Phila) 2008;47:211-9.
2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406.
3. Gould IM, David MZ, Esposito S, et al. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012;39:96-104.
4. Guay DR. Treatment of bacterial skin and skin structure infections. Expert Opin Pharmacother 2003;4:1259-75.
5. Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003;47:2370-2.
6. Beekmann SE, Heilmann KP, Richter SS, García-de-Lomas J, Doern GV; GRASP Study Group. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002Y2003. Results of the multinational GRASP Surveillance Program. Int J Antimicrob Agents 2005;25:148-56.
7. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-55.
8. Morgan M. Treatment of MRSA soft tissue infections: an overview. Injury 2011;42 Suppl 5:S11-7.
9. Skov R, Christiansen K, Dancer SJ, et al. Update on the prevention and control of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Int J Antimicrob Agents 2012;39:193-200.
10. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005;352:1436-44.
11. Locke JB, Rahawi S, Lamarre J, Mankin AS, Shaw KJ. Genetic environment and stability of CFR in methicillin-resistant Staphylococcus aureus CM05. Antimicrob Agents Chemother 2012;56:332-40.
12. Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005;40:1058-60.
13. Boyle-Vavra S, Jones M, Gourley BL, et al. Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 2011;55:2018-25.
14. Toh SM, Xiong L, Arias CA, et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007;64:1506-14.
15. Gisby J, Bryant J. Efficacy of a new creamformulation of mupirocin: comparison with oral and topical agents in experimental skin infections. Antimicrob Agents Chemother 2000;44:255-60.
16. Howden BP, GraysonML. Dumb and dumberVthe potentialwaste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006;42: 394-400.
17. Jones JC, Rogers TJ, Brookmeyer P, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007;45:541-7.
18. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003;51:613-7.
19. Traub WH, Leonhard B. Comparative susceptibility of clinical group A, B, C, F, and G betahemolytic streptococcal isolates to 24 antimicrobial drugs. Chemotherapy 1997;43:10-20.
20. Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother 2006;50:3882-5.
21. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci. Antimicrob Agents Chemother 2006;50:2583-6.
22. Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%. Expert Rev Anti Infect Ther 2009;7:269-79.
23. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid andmupirocin. J Antimicrob Chemother 2008;62:766-8.
24. Altabax 10 mg/g ointment [prescribing information]. https://www.gsksource.com/gskprm/htdocs/documents/ALTABAX.PDF. Last accessed May 24, 2012.
25. Altargo 10 mg/g ointment. Summary of product characteristics. http://www.ema.europa eu/docs/en-GB/document-library/EPAR-Product-Information/human/000757/WC500024409. pdf. Last accessed May 24, 2012.
26. Free A, Roth E, Dalessandro M, et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. Skinmed 2006;5:224-32.
27. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 2007;215:331-40.
28. Parish LC, Jorizzo JL, Breton JJ, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: results of a randomized controlled trial. J Am Acad Dermatol 2006;55:1003-13.
29. Zyvox [prescribing information]. New York: Pfizer. http://labeling.pfizer.com/showlabeling. aspx?id=649. Last accessed October 8, 2014.
30. Breneman DL. Use of mupirocin ointment in the treatment of secondarily infected dermatoses. J Am Acad Dermatol 1990;22 (5 Pt 1):886-92.
31. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. 17th Informational Supplement. CLSI document M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
32. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008;158:1077-82.
33. Kardas P, Devine S, Golembesky A, Roberts C. A systematic review and meta-analysis of misuse of antibiotic therapies in the community. Int J Antimicrob Agents 2005;26:106-13.
34. Rist T, Parish LC, Capin LR, Sulica V, Bushnell WD, Cupo MA. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. Clin Exp Dermatol 2002;27:14-20.